You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥去年度淨虧損擴大至1.06億美元
阿思達克 03-04 16:13
和黃醫藥公布,2019年度收入達2.049億美元(下同),按年下跌4.29%,淨虧損擴大至1.06億元,對比2018年同期為虧蝕7,480萬元。集團表示,目前在全球範圍內共有8個抗癌類候選藥物在開發中,並在中國具有廣泛的商業網絡,2019年首個上市的藥物愛優特最近被納入中國國家醫保藥品目錄。愛優特於去年銷售額錄1,760萬元,今年首兩個月則達660萬元。和黃醫藥主席杜志強表示,展望今年,用於治療非胰腺神經內分泌瘤的抗癌候選藥物索凡替尼(Surufatinib)有望在年底上市,中國腫瘤商業化團隊目前有140多名員工,計劃再招募約300-350名銷售人員。集團亦計劃提交另外兩項新藥上市申請,預計產品可在2021年上市。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account